Recently, the results of the phase I trials have revealed that prostate-specific membrane antigen (PSMA) CAR T optimally engineered with TGF-βRII to block TGF-β signaling to demonstrate improved T cell expansion in blood, tumor trafficking, and enhanced antitumor immunity in metastatic castration-resistant prostate cancer (41). Here, FOLH1 is linked to neoplasm.